Pharming Group NV: RUCONEST (rhC1INH) marketed to treat acute Hereditary Angioedema (HAE) attacks with 100% response rate, no relapse, side effects, or plasma risk. Only product with future potential to be approved for both prophylaxis and treatment of attacks of HAE. Profitable, cash flow positive. Announced positive results from a ph2 study of RUCONEST in Contract-induced Nephropathy for patients receiving elective coronary angiography with or without a percutaneous coronary intervention (PCI). Pursuing new delivery formulations and larger indications for RUCONEST/rhC1INH, including 2019 clinical trials in pre-eclampsia and acute kidney injury, and development programs in Pompe and Fabry diseases.
Based in...
Clinical Stage
Disease Space
Anti-inflammatory, Autoimmune, Rare Disease
Profitable, Revenues
Europe, Public
Market Cap
500MM +
Therapeutic Modalities
Recombinant DNA
Darwinweg 24
Leiden, 2333 CR

Company Participants at Jefferies Global Healthcare Conference London Nov 2018

  • Sijmen de Vries, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.